Experimental breast cancer drug holds promise in combination therapy for Ewing sarcoma

Share this content:
Experimental breast cancer drug holds promise in combination therapy for Ewing sarcoma
Experimental breast cancer drug holds promise in combination therapy for Ewing sarcoma
Ewing sarcoma tumors disappeared and did not return in more than 70 percent of mice treated with combination therapy that included drugs from a family of experimental agents developed to fight breast cancer, reported St. The treatment paired two chemotherapy drugs currently used to treat Ewing sarcoma (EWS) with experimental drugs called poly-ADP ribose polymerase (PARP) inhibitors that interfere with DNA repair.
READ FULL ARTICLE From Medical News Today
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »